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TO THE EDITOR
Allergic diseases typically develop in
mucosal surfaces such as the skin,
airway and gastrointestinal tract. The
best described of these are atopic
dermatitis (AD), food allergy, allergic
rhinitis (AR), and asthma. More re-
cently, eosinophilic esophagitis (EE)
has also been characterized as an
atopic disorder. Genetic studies have
highlighted the importance of epithe-
lial-derived genes such as dipeptidyl
peptidase 10, serine protease inhibi-
tor–kazal-type 5, stratum corneum chy-
motryptic enzyme, and filaggrin (FLG)
in either asthma or AD or both (Morar
et al., 2006). Specific loss-of-function
mutations in the FLG gene recently
described in subjects with AD are
thought to explain, in part, the cuta-
neous barrier defects long observed in
AD (Palmer et al., 2006). Stratum
granulosum cells produce filaggrin as
they differentiate into stratum corneum
cells. Filaggrin aggregates keratin fila-
ments within the cells resulting in the
cornified envelope, which is critical for
barrier function. This work has led
many to hypothesize that the skin is a
key portal of entry for relevant allergens
and irritants that can drive both skin
and airway disease (Cork et al., 2006).
This is further supported by the evi-
dence that FLG mutations are asso-
ciated with extrinsic AD, early onset of
eczema that persists into adulthood,
and the coexistence of atopic asthma or
AR and AD (Marenholz et al., 2006;
Palmer et al., 2006; Weidinger et al.,
2007). This latter association has led to
the speculation that FLG mutations may
directly impact barrier function at other
mucosal surfaces such as airway or
gastrointestinal tracts. The mucosal
surfaces where filaggrin is expressed
have not been well characterized. An
online textbook and previous published
studies state that filaggrin immunoreac-
tivity has been observed in orthokerati-
nized and parakeratinized areas of
human oral epithelium (Smith and
Dale, 1986; Reibel et al., 1989), cervix,
endometrium, and vagina (http://
www.proteinatlas.org/tissue_profile.php?
antibody_id=2210). Whether mutations
in FLG would have a direct impact on
barrier function in other mucosal sur-
faces such as upper airway and eso-
phagus has not been well studied. To
address the lower airway, Ying et al.
(2006) recently reported the complete
absence of filaggrin immunoreactivity
in bronchial biopsies obtained from
both asthmatic and nonatopic (NA)
control subjects. Bronchial staining
(n¼3) conducted in our laboratory
have confirmed Ying’s findings (data
not shown). This data suggests that
filaggrin has no direct role in lower
Abbreviations: AD, atopic dermatitis; AR, allergic rhinitis; EE, eosinophilic esophagitis; FLG, filaggrin;
IRB, Institutional Review Board; NA, nonatopic
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airway permeability to environmental
insults such as allergens, particulate
matter, pollutants, etc.
In this study, we hypothesized that
filaggrin defects may predispose indivi-
duals either directly or indirectly to
upper airway diseases (AR, sinusitis, or
nasal polyposis) or diseases of the upper
gastrointestinal tract (food allergy or
EE). AR affects 20–40 million people in
the United States and increased muco-
sal barrier permeability has been shown
to correlate with disease severity
(Skoner, 2001). However, the nature
of this nasal barrier defect is not well
understood.
EE is characterized by the infiltration
of the esophagus with large numbers
of eosinophils. EE is typically distin-
guished from reflux esophagitis by the
presence of at least 20 eosinophils per
high power field in the esophageal
epithelium (Norvell et al., 2007).
Several lines of evidence suggest that
EE is an atopic disorder. Most subjects
with EE have a personal or family
history of asthma, AD, or AR (Norvell
et al., 2007). Multiple groups have
demonstrated a link between food
allergens and EE (Kelly et al., 1995).
Placing patients with EE on an amino-
acid-based formula leads to a decrease
in esophageal eosinophilia (Kelly et al.,
1995). Aeroallergens may also contri-
bute to the pathogenesis of EE (Kelly
et al., 1995; Norvell et al., 2007).
This study received an Institutional
Review Board (IRB) exemption from the
University of Rochester Medical Center,
as all samples were deidentified. Nasal
biopsies of inferior turbinates from NA
subjects (n¼11) or subjects with per-
ennial AR (n¼ 8), nasal polyps (n¼ 5),
and esophageal biopsies (6 from prox-
imal, 10 from mid- and 10 from distal
esophageal biopsies) were analyzed in
this study (Table 1). We used skin
biopsies (n¼ 10) from NA controls and
oral mucosal biopsies (n¼7) as positive
controls (Table 1). All samples were
received in a deidentified fashion from
the pathology department at our institu-
tion or from previous IRB-
approved protocols. All biopsies were
formalin-fixed and paraffin-embedded.
Five-micron sections were mounted on
glass slides, dewaxed, and rehydrated.
Target retrieval was performed, with a
citrate solution (Zymed, Invitrogen
Corporation, Carlsbad, CA). Endo-
genous peroxidase was blocked (Dako,
Carpinteria, CA), and nonspecific Ig-
binding sites were blocked with Protein
Block Serum Free (Dako). Briefly,
sections were incubated overnight
at 41C with a mouse monoclonal
anti-human Filaggrin (SPM181;
Abcam, Cambridge, MA) at a final
concentration of 0.4 mgml1. Purified
nonimmune mouse IgG1 (0.4 mgml
1;
Sigma, St. Louis, MO) was used to
evaluate background staining. Sections
were washed in phosphate-buffered
saline buffer and then incubated with
biotinylated goat anti-mouse antibody
(Vector, Burlingame, CA) for 1 h at
room temperature. Sections were incu-
bated with alkaline phosphate standard
avidin–biotin complex mixture (Vector)
for 20min at room temperature. To
allow visualization of filaggrin, sections
were incubated with Permanent Red
(Dako) and then counterstained with
Gills’ Hematoxylin (Sigma).
Filaggrin immunoreactivity was un-
detectable in all nasal (NA, n¼11;
perennial AR, n¼8; and nasal polyps,
n¼5) and esophageal (distal, n¼10;
mid-, n¼ 10; proximal, n¼6) biopsies
(Table 1 and Figure 1). In contrast, all
NA skin (n¼10) and oral mucosa
(n¼7) biopsies (Figure 2) demonstrated
intense and continuous filaggrin stain-
ing in the stratum granulosum and
corneum and no immunoreactivity
was observed in IgG1 controls (data
not shown). The anti-filaggrin mouse
mAb (SPM181; Abcam) used for the
study was raised against the recombi-
nant full-length protein. Therefore, we
cannot exclude the fact that this anti-
body could detect both filaggrin as well
as profilaggrin.
In summary, based on our immuno-
histochemical analysis, filaggrin is not
expressed in normal upper airway or
esophageal epithelium (proximal as
well as distal) and is therefore unlikely
to play a role in barrier function at these
mucosal surfaces. These findings
strongly suggest that FLG mutations
are not directly involved in the barrier
dysfunction thought to be a feature of
AR, nasal polyposis, sinusitis, EE, or
asthma. Sequential biopsies from proxi-
mal to distal nasal cavity (including
vestibule, septal, all turbinates) should
be done prospectively in healthy in-
dividuals to determine the extent to
which filaggrin is expressed in these
areas and at what point in the transition
from oral to nasal cavity is filaggrin
immunoreactivity lost. We suspect that
barrier dysfunction in the nasal, eso-
phageal, or lung epithelium would
more likely involve defects in proteins
important for intercellular junction for-
mation (e.g., tight junctions, adherens
junctions, gap junctions, and desmo-
somes), which we believe may also be
relevant for barrier dysfunction in
AD (De Benedetto et al., 2007). In
summary, our studies strongly suggest
that FLG mutations would not have
direct effects on barrier function in the
upper or lower airway or esophagus;
Table 1. Pathology samples stained for filaggrin
Biopsy Clinical diagnosis Anatomical location Filaggrin staining
Skin NA Lower back (n=10) +
Oral mucosa Normal mucosa Hard palate (n=5) +
Oral mucosa Normal mucosa Buccal mucosa (n=1) +
Oral mucosa Hyperkeratotic mucosa Right alveolar ridge (n=1) +
Nasal mucosa NA Inferior turbinate (n=11) 
Nasal mucosa AR Inferior turbinate (n=8) 
Nasal mucosa Nasal polyp Inferior turbinate (n=5) 
Esophageal mucosa Normal mucosa Proximal (n=6) 8–19 cm1 
Esophageal mucosa Normal mucosa Mid (n=10) 19–30 cm1 
Esophageal mucosa Normal mucosa Distal (n=10) 30–41 cm1 
AR, allergic rhinitis; NA, nonatopic.
1Measured from teeth at the time of endoscopy.
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however, we cannot exclude that such
mutations (or acquired defects) in filag-
grin may indirectly play a role in the
development of atopic disorders in dis-
tant organs (Howell et al., 2007). Future
studies will likely determine whether and
how oral and cutaneous barrier defects
can affect the development of allergic
diseases in distant organs.
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Figure 1. Filaggrin is not expressed in normal and allergic upper airway or esophageal epithelium
(distal, mid- or proximal). Filaggrin immunoreactivity was undetectable in esophageal mucosa
obtained from distal, mid-, or proximal locations (representative example of n¼26; (a)  100
and (b) corresponding  400 magnification of the selected area in (a)). Nasal biopsies of inferior
turbinates obtained from NA control subjects (representative example of n¼ 11; (c) 100 and
(d) corresponding  400 magnification of the selected area in (c)) or subjects with perennial AR
(representative example of n¼8; (e)  100 and (f) corresponding  400 magnification of the selected
area in (e)) also had no filaggrin reactivity. Bar¼100 mm.
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Figure 2. Filaggrin is expressed in the epithelium of skin and oral mucosa. Intense and continuous
filaggrin staining was detectable in the stratum granulosum and corneum of skin from healthy subjects
with no skin disease (representative example of n¼ 10; (a) 100 and (b) corresponding  400
magnification of the selected area in (a)) and in healthy oral mucosa (hard palate, which is a
representative example of n¼ 7; (c)  100 and (d) corresponding  400 magnification of the
selected area in (c)). Bar¼ 100mm.
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TO THE EDITOR
Cockayne syndrome (CS) is character-
ized by various clinical manifestations
such as postnatal growth failure and
progressive neurological dysfunction,
but it conveys no predisposition to skin
cancer. CS can be caused by mutation
in two genes, CKN1/CSA and ERCC6/
CSB. CSA and CSB protein play a key
role in transcription-coupled DNA re-
pair, which removes UV-induced DNA
lesions only in the actively transcribed
DNA strand (Hanawalt, 2002). CS was
classified into three clinical subtypes:
classical, severe, and mild CS (Nance
and Berry, 1992). The clinical diagnosis
of classical CS requires the presence of
growth failure, neurological dysfunc-
tion, and at least three of the following:
photosensitivity, pigmentary retinopa-
thy, sensorineural hearing loss, dental
caries, and cachectic dwarfism. Mild
CS patients have some of the clinical
signs of CS but lack one or more of the
criteria, and their symptoms are mild or
late in onset. Mild CS patients also have
normal reproductive capacity.
As clinical symptoms of CS are not
associated with cellular UV hyper-
sensitivity (Lehmann, 2003), some recent
investigations have focused on activi-
ties of CSB, other than transcription-
coupled DNA repair, that might be
responsible for CS characteristics. CSB
interacts with many proteins and thus
has many possible functions (Licht
et al., 2003). Importantly, cells from
patients accumulate oxidative DNA
lesions after X-ray exposure (Tuo
et al., 2001), and the repair deficiency
of oxidative lesions is corrected by
expression of formamidopyrimidine
DNA glycosylase from Escherichia coli
(Ropolo et al., 2007).
Some CS patients rarely show slower
course than usual, resulting in survival
into adulthood (Rapin et al., 2006). We
present herein a patient with CS, named
KPSX6, who was a 49-year-old Japa-
nese woman with a history of freckling
and dry skin in sun-exposed areas,
which had developed since her teens
(Figure 1). Although she showed normal
mental development, she had growth
retardation similar to that of her five
siblings. Four siblings had no skin
lesions, but her sister had pigmentation.
Her parents were consanguineous. She
had two daughters who were normal.
When she was 47 years old, her family
noted dementia, ataxia, and hearing
loss, which had progressed over 2
years. Physical examination revealed
a remarkably small body (height,
131.7 cm; weight, 33.1 kg) with an
aged face and scoliosis. Her skin was
dry and pigmented on the neck, arms,
and legs. However, there were no skin
cancer lesions, and her hair was nor-
mal. On neurological examination, the
deep tendon reflexes were indicative of
asthenia. Her muscles showed hypo-
tonus but no atrophy, and she had
difficulty in walking. Sensory examina-
tion revealed no abnormalities, and the
cranial nerve examination was normal.
She had difficulty with hearing and
speech. She exhibited intracranial cal-
cification on computed tomography
and cerebellar atrophy on magnetic
resonance imaging. There were no
findings on ophthalmologic examina-
tion. The minimal erythema dose
Figure 1. Clinical manifestation of patient KPSX6. Photograph of the (a) face and (b) arm.
Abbreviations: CS, Cockayne syndrome; UVSS, UV-sensitive syndrome
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Mild form of Cockayne Syndrome
